-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JDs6voHmO1xdh9z6qX5GW7XEA+hC6hzdCbRnvh6drGdGHczJ5NQuRdmIpWuVhcP4 W0BbXbUpKwDF4ipWKOVCxA== 0000950123-01-502918.txt : 20010524 0000950123-01-502918.hdr.sgml : 20010524 ACCESSION NUMBER: 0000950123-01-502918 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20010523 GROUP MEMBERS: BRUCE J HABER GROUP MEMBERS: FHS ENTERPRISES LLC GROUP MEMBERS: LOUIS BUTHER GROUP MEMBERS: ROYCE KANOFSKY SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MOORE MEDICAL CORP CENTRAL INDEX KEY: 0000074691 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES [5047] IRS NUMBER: 221897821 STATE OF INCORPORATION: DE FISCAL YEAR END: 0102 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-07421 FILM NUMBER: 1646419 BUSINESS ADDRESS: STREET 1: PO BOX 1500 STREET 2: 389 JOHN DOWNEY DR CITY: NEW BRITAIN STATE: CT ZIP: 06050 BUSINESS PHONE: 2038263600 MAIL ADDRESS: STREET 1: 389 JOHN DOWNEY DRIVE STREET 2: 389 JOHN DOWNEY DRIVE CITY: NEW BRITAIN STATE: CT ZIP: 06050 FORMER COMPANY: FORMER CONFORMED NAME: OPTEL CORP DATE OF NAME CHANGE: 19850611 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: FHS ENTERPRISES LLC CENTRAL INDEX KEY: 0001136503 STANDARD INDUSTRIAL CLASSIFICATION: [] FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 145 HUGUENOT STREET SUITE 402 CITY: NEW ROCHELLE STATE: NY ZIP: 10801 BUSINESS PHONE: 9142355550 MAIL ADDRESS: STREET 1: 145 HUGUENOT STREET SUITE 402 CITY: NEW ROCHELLE STATE: NY ZIP: 10801 SC 13D/A 1 y49649sc13da.txt AMENDMENT NO. 1 TO SCHEDULE 13D 1 SCHEDULE 13D Page 1 of 9 SEC POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION 1746 CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM (2-98) DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER. ========================== OMB APPROVAL ========================== OMB Number: 3235-0145 -------------------------- Expires: October 31, 2002 -------------------------- Estimated average burden hours per response... 14.9 ========================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* Moore Medical Corp. (Name of Issuer) Common Stock, $.01 Par Value (Title of Class of Securities) 615799103 (CUSIP Number) David Selangut, ESQ. c/o 370 Lexington Avenue, New York, NY 10017 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 18, 2001 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(F) or 240.13d-1(g), check the following box. [ ] NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 SCHEDULE 13D CUSIP NO. 615799103 PAGE 2 OF 9 - -------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOs. OF ABOVE PERSONS (ENTITIES ONLY) Bruce J. Haber - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) X (a) / / (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) PF - -------------------------------------------------------------------------------- 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION United States - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES 60,750 BENEFICIALLY ----------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH REPORTING 12,500 PERSON ----------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER 60,750 ----------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 12,500 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 73,250 - -------------------------------------------------------------------------------- 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.31% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (See Instructions) IN - -------------------------------------------------------------------------------- 3 SCHEDULE 13D CUSIP NO. 615799103 PAGE 2 OF 9 - -------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOs. OF ABOVE PERSONS (ENTITIES ONLY) Royce Kanofsky - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) X (a) / / (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) PF - -------------------------------------------------------------------------------- 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION United States - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES 71,650 BENEFICIALLY ----------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH REPORTING 500 PERSON ----------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER 71,650 ----------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 500 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 72,150 - -------------------------------------------------------------------------------- 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.27% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (See Instructions) IN - -------------------------------------------------------------------------------- 4 SCHEDULE 13D CUSIP NO. 615799103 PAGE 2 OF 9 - -------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOs. OF ABOVE PERSONS (ENTITIES ONLY) Louis Buther - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) X (a) / / (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) PF - -------------------------------------------------------------------------------- 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION United States - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES 12,800 BENEFICIALLY ----------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH REPORTING PERSON ----------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER 12,800 ----------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 12,800 - -------------------------------------------------------------------------------- 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.41% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (See Instructions) IN - -------------------------------------------------------------------------------- 5 SCHEDULE 13D CUSIP NO. 615799103 PAGE 2 OF 9 - -------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOs. OF ABOVE PERSONS (ENTITIES ONLY) FHS Enterprises LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) X (a) / / (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) WC - -------------------------------------------------------------------------------- 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION New York - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES 500 BENEFICIALLY ----------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH REPORTING PERSON ----------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER 500 ----------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 500 - -------------------------------------------------------------------------------- 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.02% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (See Instructions) CO - -------------------------------------------------------------------------------- 6 Item 1 Security and Issuer 1) Common Stock, $0.01 par value (the "Shares") Moore Medical Corp. (the "Issuer") P.O. Box 1500 389 John Downey Drive New Britain, CT 06050 Item 2 Identity and Background 1.a) Bruce J. Haber b) 65 The Oaks Roslyn, NY 11576 c) President, CEO, Director of MedConduit.com d-e) There has been no convictions, proceedings or securities violations in the past 5 years. f) U.S. Citizen 2.a) Royce Kanofsky b) 1665 Warwick Road Hewlett, NY 11557 c) Investment Banking d-e) There has been no convictions, proceedings or securities violations in the past 5 years. f) U.S. Citizen 3.a) Louis Buther b) 205 Ridgefield Avenue South Salem, N.Y. 10590 c) Consultant d-e) There has been no convictions, proceedings or securities violations in the past 5 years. f) U.S. Citizen 4.a) FHS Enterprises LLC ("FHS") b) 145 Huguenot Street, Suite 402 New Rochelle, NY 10801 Mr. Haber and Mr. Kanofsky are both members of FHS. c) FHS Enterprises LLC was organized to acquire and hold securities. d-e) N/A 7 f) FHS Enterprises LLC is a New York Limited Liability Company organized on February 21, 2001 The aforementioned parties together will be referred to as the "Reporting Parties." Item 3 Source and Amount of Funds or Other Consideration 1. The shares of common stock were purchased with personal funds of the Reporting Parties. Item 4 Purpose of Transaction The Reporting Parties acquired and continue to hold the Shares for investment purposes. They would like to assist the Issuer in identifying new strategies to enhance shareholder value and maximize investments in both its core business and e-commerce. The Reporting Party intends to seek removal of the Company's "Poison Pill" and has requested that the Board of the Company make sure Management incentives are aligned with creating shareholder value and preserving the shareholders' portion of the Company's enterprise value. Each of the Reporting Parties intends to review his or its investment in the Issuer on a continuing basis and, depending on market conditions, the Issuer's business and financial condition, and other material factors, each of the Reporting Parties may purchase additional shares of Common Stock or sell some or all of their holdings in a public or private transaction. The Reporting Parties have no present plans or proposals that relate to or that would result in any of the actions specified in clauses (a)-(j) of Item 4 of Schedule 13D of the Act. Item 5 Interest in Securities of the Issuer The Reporting Parties Hereby amend Item 5 as follow: 1. Bruce J. Haber a-b) Mr. Bruce J. Haber may be deemed to beneficially own 73,250 shares of the Common Stock, which constitutes approximately 2.31% of the outstanding shares of Common Stock (based on the 3,153,943 shares of Common Stock outstanding as of April 27, 2001 as reported on the Quarterly Report on Form 10-Q filed by the Company on March 31, 2001). Of these shares: i) 55,750 shares of Common Stock are owned directly by Mr. Haber. ii) 12,000 shares are owned by his wife, Mr. Haber disclaims beneficial ownership of the shares held by his wife. 8 iii) 5,000 shares are own by his daughter in a custodian account in which Mr. Haber is the custodian. iv) 500 shares are attributed to Mr. Haber by virtue of his part ownership of FHS. c) Mr. Bruce J. Haber purchased 800 shares on May 18, 2001. Mr. Haber, Mr. Kanofsky, Mr. Buther and FHS, as a group beneficially own 5.01% of the Company's shares of Common Stock. 2. Royce Kanofsky a-b) Mr. Royce Kanofsky beneficially owns 72,150 shares of the Common Stock, which constitutes approximately 2.27% of the outstanding shares of Common Stock. Of these shares, 71,650 are owned directly by Mr. Kanofsky and 500 shares are attributed to him by virtue of his part ownership of FHS. c) Mr. Royce Kanofsky purchased 800 shares on May 18, 2001. Mr. Haber, Mr. Kanofsky, Mr. Buther and FHS, as a group beneficially own 5.01% of the Company's shares of Common Stock. 3. Louis Buther a-b) Mr. Louis Buther beneficially owns 12,800 shares of the Common Stock, which constitutes approximately 0.41% of the outstanding shares of Common Stock. Mr. Haber, Mr. Kanofsky, Mr. Buther and FHS, as a group beneficially own 5.01% of the Company's shares of Common Stock. 4. FHS a-b) FHS beneficially owns 500 shares of the Common Stock, which constitutes approximately 0.02% of the outstanding shares of Common Stock. Mr. Haber, Mr. Kanofsky, Mr. Buther and FHS, as a group beneficially own 5.01% of the Company's shares of Common Stock. Item 6 Contracts, Arrangements, Understandings or Relationships With Respect to the Securities of the Issuer NONE 9 Item 7 Material Exhibits to be filed EXHIBIT A - A letter from Bruce J. Haber of FHS Enterprises, LLC to Moore Medical Corp. dated May 4, 2001. After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. Date: May 21, 2001 FHS Enterprises LLC By: /s/ Bruce J. Haber ------------------ Bruce J. Haber President /s/ Bruce J. Haber ------------------ Bruce J. Haber /s/ Royce Kanofsky ------------------ Royce Kanofsky /s/ Louis Buther ---------------- Louis Buther EX-99.A 2 y49649ex99-a.txt LETTER FROM BRUCE J. HABER 1 EXHIBIT A Letter from Bruce J. Haber of FHS Enterprises, LLC to Moore Medical Corp. dated May 4, 2001. (See Attached) 2 Bruce J. Haber FHS Enterprises, LLC 145 Huguenot Street, Suite 402 New Rochelle, New York 10801 VIA FEDERAL EXPRESS May 4, 2001 Mr. Robert H. Steele Chairman of the Board Moore Medical Corp. 389 John Downey Drive New Britain, CT 06050 Dear Mr. Steele, On February 26, 2001 we met and discussed i) my desire to assist the Company and use my considerable medical distribution experience to help Moore Medical improve its financial performance in return for the opportunity to purchase an additional 500,000 shares of stock from the Company, subject to the Company amending or rescinding its poison pill in order to allow such purchase, ii) the large amounts being invested in a questionable E-Commerce strategy, and iii) the extraordinarily large and continuing operating losses recently incurred by the Company. The offers were refused with an explanation that the Board felt satisfactory progress was being made by management toward implementation of its business plans and help was not needed. Subsequent to our last conversation the Company disclosed in its 10-K filing additional details regarding the continued deterioration of its operating performance. Most enlightening was the 84% increase in advertising expense which resulted in only a nominal sales increase and accelerating quarterly operating losses. Also revealed in the 10-K were recent actions to entrench and enrich management. New contracts were signed and bonus plans enacted that will pay large rewards for continued mediocre or worse performance. It is hard to understand how top executives are entitled to yearend bonuses of 25% of base salary for attainment of a mere 10% sales increase, with little regard to profitability or shareholder value. It appears management is spending shareholder dollars to reach their bonus goals at any cost. I called you several times to discuss these issues and have not even received the courtesy of a return call. Last week the Company reported a 9% sales increase for the first quarter and another huge operating loss of $1.8 million. The Company's press release noted that there was again an increase in advertising costs. We question why there continues to be relatively little return for the large amounts being expended and further wonder if the Company is being disingenuous in trumpeting "the highest quarterly growth rate in more than five years" given public statements by 3 competitors that the first quarter of 2000 was adversely affected by increased Y2K spending at the end of 1999. We feel it is time for the Board to act on its duty to shareholders to enhance the value of the Company's common stock by reevaluating the current business strategy, reviewing the effectiveness of the advertising and E-Commerce expenditures, and making sure management incentives are aligned with creating shareholder value and preserving the shareholders' portion of the Company's enterprise value. Further, it is imperative for the poison pill to be removed so as to allow other options for the creation of value to be explored. We have reason to believe that approaches to the Company by potential merger partners have been summarily rebuffed. I look forward to hearing from you so that we may discuss these matters. Sincerely, /s/ Bruce J. Haber - ----------------------------------- Bruce J. Haber President 2 -----END PRIVACY-ENHANCED MESSAGE-----